Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial.
<h4>Objective</h4>To determine if men who have sex with men (MSM) with cocaine use disorder (CUD) and actively-using cocaine could be enrolled and retained in a pharmacologic intervention trial of lorcaserin-a novel 5-HT2cR agonist-and determine the degree to which participants would adh...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254724&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595711536922624 |
|---|---|
| author | Glenn-Milo Santos Janet Ikeda Phillip Coffin John E Walker Tim Matheson Matthew McLaughlin Jennifer Jain Eric Vittinghoff Steven L Batki |
| author_facet | Glenn-Milo Santos Janet Ikeda Phillip Coffin John E Walker Tim Matheson Matthew McLaughlin Jennifer Jain Eric Vittinghoff Steven L Batki |
| author_sort | Glenn-Milo Santos |
| collection | DOAJ |
| description | <h4>Objective</h4>To determine if men who have sex with men (MSM) with cocaine use disorder (CUD) and actively-using cocaine could be enrolled and retained in a pharmacologic intervention trial of lorcaserin-a novel 5-HT2cR agonist-and determine the degree to which participants would adhere to study procedures.<h4>Methods</h4>This was a phase II randomized, double-blind, placebo-controlled pilot study with 2:1 random parallel group assignment to daily extended-release oral lorcaserin 20 mg versus placebo (clinicaltrials.gov identifier-NCT03192995). Twenty-two of a planned 45 cisgender MSM with CUD were enrolled and had weekly follow-up visits during a 12-week treatment period, with substance use counseling, urine specimen collection, and completion of audio-computer assisted self-interview (ACASI) behavioral risk assessments. Adherence was measured by medication event monitoring systems (MEMS) caps and self-report. This study was terminated early because of an FDA safety alert for lorcaserin's long-term use.<h4>Results</h4>Eighty-six percent completed the trial, with 82% of weekly study follow-up visits completed. Adherence was 55.3% (lorcaserin 51.6% vs. placebo 66.2%) by MEMS cap and 56.9% (56.5% vs. placebo 57.9%) by self-report and did not differ significantly by treatment assignment. Intention-to-treat analyses (ITT) did not show differences in cocaine positivity by urine screen between the lorcaserin and placebo groups by 12 week follow-up (incidence risk ratio [IRR]: 0.96; 95%CI = 0.24-3.82, P = 0.95). However, self-reported cocaine use in timeline follow-back declined more significantly in the lorcaserin group compared to placebo (IRR: 0.66; 95%CI = 0.49-0.88; P = 0.004).<h4>Conclusion</h4>We found that it is feasible, acceptable, and tolerable to conduct a placebo-controlled pharmacologic trial for MSM with CUD who are actively using cocaine. Lorcaserin was not associated with significant reductions in cocaine use by urine testing, but was associated with significant reductions in self-reported cocaine use. Future research may be needed to continue to explore the potential utility of 5-HT2cR agonists. |
| format | Article |
| id | doaj-art-c80071f524e1403eab5b8ecb697829f9 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c80071f524e1403eab5b8ecb697829f92025-01-18T05:31:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025472410.1371/journal.pone.0254724Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial.Glenn-Milo SantosJanet IkedaPhillip CoffinJohn E WalkerTim MathesonMatthew McLaughlinJennifer JainEric VittinghoffSteven L Batki<h4>Objective</h4>To determine if men who have sex with men (MSM) with cocaine use disorder (CUD) and actively-using cocaine could be enrolled and retained in a pharmacologic intervention trial of lorcaserin-a novel 5-HT2cR agonist-and determine the degree to which participants would adhere to study procedures.<h4>Methods</h4>This was a phase II randomized, double-blind, placebo-controlled pilot study with 2:1 random parallel group assignment to daily extended-release oral lorcaserin 20 mg versus placebo (clinicaltrials.gov identifier-NCT03192995). Twenty-two of a planned 45 cisgender MSM with CUD were enrolled and had weekly follow-up visits during a 12-week treatment period, with substance use counseling, urine specimen collection, and completion of audio-computer assisted self-interview (ACASI) behavioral risk assessments. Adherence was measured by medication event monitoring systems (MEMS) caps and self-report. This study was terminated early because of an FDA safety alert for lorcaserin's long-term use.<h4>Results</h4>Eighty-six percent completed the trial, with 82% of weekly study follow-up visits completed. Adherence was 55.3% (lorcaserin 51.6% vs. placebo 66.2%) by MEMS cap and 56.9% (56.5% vs. placebo 57.9%) by self-report and did not differ significantly by treatment assignment. Intention-to-treat analyses (ITT) did not show differences in cocaine positivity by urine screen between the lorcaserin and placebo groups by 12 week follow-up (incidence risk ratio [IRR]: 0.96; 95%CI = 0.24-3.82, P = 0.95). However, self-reported cocaine use in timeline follow-back declined more significantly in the lorcaserin group compared to placebo (IRR: 0.66; 95%CI = 0.49-0.88; P = 0.004).<h4>Conclusion</h4>We found that it is feasible, acceptable, and tolerable to conduct a placebo-controlled pharmacologic trial for MSM with CUD who are actively using cocaine. Lorcaserin was not associated with significant reductions in cocaine use by urine testing, but was associated with significant reductions in self-reported cocaine use. Future research may be needed to continue to explore the potential utility of 5-HT2cR agonists.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254724&type=printable |
| spellingShingle | Glenn-Milo Santos Janet Ikeda Phillip Coffin John E Walker Tim Matheson Matthew McLaughlin Jennifer Jain Eric Vittinghoff Steven L Batki Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. PLoS ONE |
| title | Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. |
| title_full | Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. |
| title_fullStr | Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. |
| title_full_unstemmed | Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. |
| title_short | Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. |
| title_sort | pilot study of extended release lorcaserin for cocaine use disorder among men who have sex with men a double blind placebo controlled randomized trial |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254724&type=printable |
| work_keys_str_mv | AT glennmilosantos pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT janetikeda pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT phillipcoffin pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT johnewalker pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT timmatheson pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT matthewmclaughlin pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT jenniferjain pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT ericvittinghoff pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial AT stevenlbatki pilotstudyofextendedreleaselorcaserinforcocaineusedisorderamongmenwhohavesexwithmenadoubleblindplacebocontrolledrandomizedtrial |